Biomx Inc (PHGE)

The Cystic Fibrosis Foundation has filed an Amendment No. 5 to a Schedule 13G/A, reporting its beneficial ownership in BiomX Inc. (PHGE). The foundation now holds 174,276 shares, which represents 1.47% of the common stock, indicating their ownership is now 5% or less of the company. They maintain sole voting and dispositive power over these shares.

BiomX Inc. (PHGE) has announced a significant strategic shift from phage-based drug development to defense, security, and critical infrastructure technology, following substantial losses and a cash balance of only $0.3 million. The company acquired ZorroNet and a 60% stake in DFSL, boosting its assets to $28.2 million and stockholders' equity to $17.6 million, but still reported a net loss of $23.0 million for the first half of 2026. Management has expressed substantial doubt about its ability to continue as a going concern without additional financing, planning to rely on equity/debt raises and revenue from its new acquisitions.

BiomX Inc. reported its first quarter of recognized revenue, reaching $0.33 million for Q2 2026, following its April acquisitions. The company posted a net loss of $3.85 million and an EPS of ($0.36), showing improvement compared to the previous year. This shift follows a strategic pivot from biopharma to defense and security markets, with initial product deployments and framework agreements already secured.

BiomX Inc. announced its financial results for the second quarter and first six months of 2026. For the second quarter, the company reported sales of $0.332 million and a net loss of $3.77 million, significantly reduced from $6.04 million in the prior year. The six-month period saw sales of $0.332 million and a net loss of $22.91 million, an increase from $13.7 million a year ago.

BiomX Inc. announced that its subsidiary, Zorronet Ltd., received a $300,000 order to establish a unified operational environment at a defense technology test and evaluation site. This project involves designing communications, computing, and control infrastructure, integrating systems, and deploying a command-and-control center. The initiative aims to enhance coordination across site security, safety, operations, and testing activities, marking a strategic expansion for Zorronet in defense technology.